Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

2023 New England Journal of Medicine 605 citations

Abstract

After 15 years of follow-up, prostate cancer-specific mortality was low regardless of the treatment assigned. Thus, the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer. (Funded by the National Institute for Health and Care Research; ProtecT Current Controlled Trials number, ISRCTN20141297; ClinicalTrials.gov number, NCT02044172.).

Keywords

Prostate cancerMedicineRadiation therapyCancerGeneral surgeryOncologySurgeryInternal medicine

MeSH Terms

HumansMaleAndrogen AntagonistsAndrogensFollow-Up StudiesProstate-Specific AntigenProstatectomyProstatic NeoplasmsWatchful WaitingMiddle AgedAgedRadiotherapyRisk Assessment

Affiliated Institutions

Related Publications

Publication Info

Year
2023
Type
article
Volume
388
Issue
17
Pages
1547-1558
Citations
605
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

605
OpenAlex
12
Influential
569
CrossRef

Cite This

Freddie C. Hamdy, Jenny Donovan, J. Athene Lane et al. (2023). Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine , 388 (17) , 1547-1558. https://doi.org/10.1056/nejmoa2214122

Identifiers

DOI
10.1056/nejmoa2214122
PMID
36912538

Data Quality

Data completeness: 90%